Sartorius equipment. (photo credit: Sartorius AG / )
(CercleFinance.com) – On the occasion of a preliminary publication, Sartorius Stedim Biotech reduced its forecasts for 2023, now expecting a drop in its turnover of almost 19% (and around 14% % excluding items linked to Covid-19) at constant exchange rates.
According to the supplier to the pharmaceutical industry, its current EBITDA margin should now be slightly higher than 28% this year, whereas it was previously anticipated at around 30%, and compared to 35% in the previous financial year. .
According to its preliminary figures, the group recorded a turnover of around 2.07 billion euros in the first nine months of 2023, a decline of almost 19% at constant exchange rates, and its Current EBITDA margin fell six points to 29%.